SCYNEXIS INC
No SEC Form 4 filings for $SCYX in the last 30 days.
See all $SCYX insider activity →SCYNEXIS (SCYX) reported positive Phase 1 results for IV SCY-247, an antifungal candidate. The drug was well tolerated in 56 healthy participants, with no serious adverse events. Doses of 50 mg or higher met target exposure. Phase 2 development is planned for 2027, with up to $214M in potential BARDA funding. The stock is up 2.04% at $3.86.
SCYNEXIS reported that SCY-770 was well tolerated in a Phase 1 study, supporting dose selection. The company plans to start a Phase 2 trial for ADPKD in Q4 2026. According to the company, this is an early clinical de-risking step.
SCYNEXIS (SCYX) reported positive Phase 1 results for SCY-770, a potential first-in-class oral direct AMPK activator for ADPKD. The study showed favorable safety and tolerability, with Phase 2 initiation on track for Q4 2026. SCY-770 has Orphan Drug Designation from the FDA.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SCYX (SCYNEXIS INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SCYX coverage spans financial news, corporate actions and technology.
Positive early‑stage data should lift sentiment and create buying pressure.
Phase 1 safety data reduces development risk and may boost the stock.
Positive Phase 1 data may lift the stock as investors price in reduced development risk.
The contract provides substantial non‑dilutive funding, de‑risking the SCY‑247 program and extending cash runway.
The non‑dilutive BARDA award provides significant runway for SCY‑247, likely supporting further upside.
AlphAI scores every news story that mentions SCYX with an AI model for sentiment and relevance, and aggregates insider trades from SCYNEXIS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
SCYNEXIS (SCYX) reported positive Phase 1 results for IV SCY-247, an antifungal candidate. The drug was well tolerated in 56 healthy participants, with no serious adverse events. Doses of 50 mg or higher met target exposure. Phase 2 development is planned for 2027, with up to $214M in potential BARDA funding. The stock is up 2.04% at $3.86.
2 min readSCYNEXIS reported that SCY-770 was well tolerated in a Phase 1 study, supporting dose selection. The company plans to start a Phase 2 trial for ADPKD in Q4 2026. According to the company, this is an early clinical de-risking step.
1 min readSCYNEXIS (SCYX) reported positive Phase 1 results for SCY-770, a potential first-in-class oral direct AMPK activator for ADPKD. The study showed favorable safety and tolerability, with Phase 2 initiation on track for Q4 2026. SCY-770 has Orphan Drug Designation from the FDA.
2 min readSCYNEXIS INC (SCYX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 • BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, a
2 min readScynexis (SCYX) stock rose 13.9% in pre-market trading after securing a contract with BARDA for up to $214 million to develop its antifungal candidate SCY-247. The funding, non-dilutive and potentially spanning 10 years, will support Phase 2 trials. CEO David Angulo highlighted the partnership's role in combating antimicrobial resistance. The broader market declined, indicating the surge was company-specific.
2 min readSCYNEXIS INC (SCYX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industry JERSEY CITY, N.J., September 22, 2026 – SCYNEXIS, Inc.
1 min readSCYNEXIS INC (SCYX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies. JERSEY CITY, N.J., Septembe
1 min readSCYNEXIS INC (SCYX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false --12-31 0001178253 0001178253 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J
3 min readSCYNEXIS (NASDAQ: SCYX) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-10 to maintain its listing on The Nasdaq Capital Market. The virtual special meeting is scheduled for May 19, 2026, where shareholders will vote on the proposal to increase the per-share price and avoid potential delisting proceedings by June 15, 2026. If approved, the board will have the discretion to determine the exact ratio and implement the split, which will proportionally reduce outstanding shares and adjust equity incentive plans.
2 min readJERSEY CITY, N.J., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- SCYNEXIS, Inc. ( NASDAQ: SCYX ) , a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that a novel series of antifungal compounds utilizing ...
3 min read
